Market Cap: $34.22M
AL
Alterity Therapeutics Limited
ATHE
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $34.22M
Alterity Therapeutics (Ticker: ATHE) has made significant progress with its lead drug, ATH434, targeting a rare neuromuscular disorder. Recently, the U.S. Food and Drug Administration (FDA) approved k…
Alterity Therapeutics Seeks to Enhance Neurodegenerative Disease Treatments Through Innovative Approaches Alterity Therapeutics, a clinical-stage biotechnology company, focuses on developing novel the…
Alterity Therapeutics Advances in Neurodegenerative Disease Treatment Alterity Therapeutics makes significant strides in the treatment of neurodegenerative diseases, particularly focusing on alpha-syn…
Alterity Therapeutics Advances in Neurodegenerative Disease Research Alterity Therapeutics, a clinical-stage biotechnology company, focuses on developing innovative therapies for neurodegenerative dis…
### Alterity Therapeutics Advances in Neurodegenerative Disease Research Alterity Therapeutics, a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, announces si…
Alterity Therapeutics Advances Development of Novel Alzheimer’s Treatment Alterity Therapeutics is making significant strides in its quest to develop a groundbreaking treatment for Alzheimer’s disease…
Alterity Therapeutics Advances in Neurodegenerative Disease Research Alterity Therapeutics, a biotechnology company focused on developing treatments for neurodegenerative diseases, makes significant s…
Alterity Therapeutics Advances in Neurodegenerative Disease Research Alterity Therapeutics announces significant progress in its clinical development of treatments for neurodegenerative diseases, spec…
Alterity Therapeutics Advances Neurodegenerative Disease Research with New Clinical Trial Initiation Alterity Therapeutics announces the initiation of a new clinical trial focused on its innovative tr…
Alterity Therapeutics Advances Neurodegenerative Disease Research with Promising Developments Alterity Therapeutics focuses on developing treatments for neurodegenerative diseases, primarily through i…